Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LYT 200

Next Previous
Drug Profile

LYT 200

Alternative Names: LYT-200

Latest Information Update: 11 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PureTech Health
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Galectin inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 30 Apr 2025 Updated efficacy and adverse events data from a phase Ib trial in Myelodysplastic syndromes and Acute myeloid leukaemia released by PureTech Health
  • 24 Feb 2025 CTP push- 700314690- Trial completed- KDM and HE. Patient number updated
  • 09 Jan 2025 LYT 200 receives Fast Track designation for Acute myeloid leukaemia [IV,Infusion] (Monotherapy, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top